Official AMFI data
Arthkar — Understand Money, Invest Smartly
Computed from real daily NAV — not projections

₹2,000 Monthly SIP in Nippon India Pharma Fund-Growth Plan for 10 Years

If you had started a ₹2,000/month SIP on 6 Oct 2016 and never stopped — through every crash and rally — here is exactly what happened, using Nippon India Pharma Fund-Growth Plan's actual NAV for all 121 installments.

You invested

₹2,42,000

121 installments

Value today

₹5,96,064

6 Oct 2026

Absolute gain

+₹3,54,064

+146.3%

XIRR (annualised)

17.23%

money-weighted

The journey, month by month

Portfolio value Amount invested

Worst fall on the way

-19.5%

Deepest drop from peak. This is what you had to sit through.

Corrections survived

4

Falls of 10%+ during the period. Every one recovered.

Same SIP in a fixed deposit

₹3,35,817

Modelled at historical FD rates. The fund beat FD by ₹2,60,247.

Year-by-year progress

YearInvestedValueOverall gain
Year 1 (6 Oct 2017)₹26,000₹25,457-2.1%
Year 2 (8 Oct 2018)₹50,000₹55,013+10%
Year 3 (7 Oct 2019)₹74,000₹71,398-3.5%
Year 4 (6 Oct 2020)₹98,000₹1,53,683+56.8%
Year 5 (6 Oct 2021)₹1,22,000₹2,33,545+91.4%
Year 6 (6 Oct 2022)₹1,46,000₹2,41,139+65.2%
Year 7 (6 Oct 2023)₹1,70,000₹3,20,250+88.4%
Year 8 (7 Oct 2024)₹1,94,000₹5,00,675+158.1%
Year 9 (6 Oct 2025)₹2,18,000₹5,16,764+137%
Year 10 (6 Oct 2026)₹2,42,000₹5,96,064+146.3%

Best year of the journey: Year 4 (+61.1% market move) · Toughest year: Year 3 (-9.6%)

Wealth Time Machine

Watch this exact journey as a 60-second cinematic replay

Every crash headline, every recovery — with your money in it.

Try a different amount

Try a different duration

Same SIP in other Sectoral / Thematic funds

Past performance does not guarantee future returns. This page shows the historical result of the stated SIP using Nippon India Pharma Fund-Growth Plan's published NAV (source: AMFI) between 6 Oct 2016 and 6 Oct 2026; it is educational research, not investment advice. FD comparison is modelled at historical average FD rates. Mutual fund investments are subject to market risks.